Contributors: Morell,M; Pérez-Cózar,F; Marañón,C GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, PTS, Granada, Spain.; This research was funded by IMI2-JU project GA#831434 (3TR) and IMI-JU project GA#115565 118 . The JU receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA. The authors also acknowledge funding from Consejería de la Salud y Familias de la Junta de Andalucía (PIER-0118-2019 and C2-0002-1019) and Instituto de Salud Carlos III (PI18/00082), partly supported by European FEDER funds.
نبذة مختصرة : The kidney is one of the main organs affected by the autoimmune disease systemic lupus erythematosus. Lupus nephritis (LN) concerns 30-60% of adult SLE patients and it is significantly associated with an increase in the morbidity and mortality. The definitive diagnosis of LN can only be achieved by histological analysis of renal biopsies, but the invasiveness of this technique is an obstacle for early diagnosis of renal involvement and a proper follow-up of LN patients under treatment. The use of urine for the discovery of non-invasive biomarkers for renal disease in SLE patients is an attractive alternative to repeated renal biopsies, as several studies have described surrogate urinary cells or analytes reflecting the inflammatory state of the kidney, and/or the severity of the disease. Herein, we review the main findings in the field of urine immune-related biomarkers for LN patients, and discuss their prognostic and diagnostic value. This manuscript is focused on the complement system, antibodies and autoantibodies, chemokines, cytokines, and leukocytes, as they are the main effectors of LN pathogenesis. ; Yes
Processing Request
No Comments.